Sunnie S Kim

7PUBLICATIONS
59CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 31, 2025
Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.

Robert W Lentz, Julie Lang, Todd M Pitts

|Jun 30, 2025
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.

Geoffrey Ku, Lin Shen, Farshid Dayyani

|Jul 24, 2024
Risk Without Reward: Differing Patterns of Chemotherapy Use Do Not Improve Outcomes in Stage II Early-Onset Colon Cancer.

Jacob B Leary, Junxiao Hu, Alexis Leal

|Jun 13, 2024
A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer.

Robert W Lentz, Tyler J Friedrich, Patrick J Blatchford

|Apr 13, 2024
Effect of Neoadjuvant Chemotherapy on Tumor-Infiltrating Lymphocytes in Resectable Gastric Cancer: Analysis from a Western Academic Center.

Elliott J Yee, Danielle Gilbert, Jeffrey Kaplan

|Jan 11, 2024
First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors.

Anna R Schreiber, Jodi A Kagihara, Bradley R Corr

Pageof 2

Frequent Collaborators

4 joint publications

Christopher Lieu

3 joint publications

Robert W Lentz

3 joint publications

Wells A Messersmith

2 joint publications

Todd M Pitts